Conversely, Ng et el6 demonstrated that MED12-mutant phyllodes tumors yield a longer disease-free survival (DFS) compared to MED12 wild-type ones (adjusted hazard ratio: 9.99; 95%CI, 1.55-64.42); however, 89% (86/97) of patients included in the study had a benign or borderline tumor and the DFS by MED12 status in patients with B-MPT (N = 11) was not disclosed. The gene discussed is MED12; the disease is phyllodes tumor.